Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
APGE Apogee Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: APGE
Price (delayed)
$37.29
Market cap
$2.22B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.3
Enterprise value
$2.09B
We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with
Highlights
The debt has decreased by 2.5% from the previous quarter
APGE's equity has surged by 89% year-on-year but it is down by 2.4% since the previous quarter
The quick ratio has grown by 13% from the previous quarter but it has contracted by 5% YoY
APGE's net income has dropped by 117% year-on-year and by 24% since the previous quarter
The company's EPS fell by 36% QoQ
Key stats
What are the main financial stats of APGE
Market
Valuations
Earnings
Shares outstanding
59.5M
Market cap
$2.22B
Enterprise value
$2.09B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.04
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$216.87M
Net income
-$182.15M
EBIT
-$182.13M
EBITDA
-$180.25M
Free cash flow
-$172.33M
Per share
Balance sheet
Liquidity
EPS
-$3.3
EPS diluted
-$3.3
Free cash flow per share
-$3.12
Book value per share
$12.25
Revenue per share
$0
TBVPS
$13.66
Total assets
$753.95M
Total liabilities
$37.16M
Debt
$11.83M
Equity
$716.79M
Working capital
$501.15M
Debt to equity
0.02
Current ratio
18.55
Quick ratio
18.23
Net debt/EBITDA
0.72
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-23.1%
Return on equity
-24.1%
Return on invested capital
-36%
Return on capital employed
-25.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APGE stock price
How has the Apogee Therapeutics stock price performed over time
Intraday
-1.38%
1 week
-7.05%
1 month
17.26%
1 year
-29.54%
YTD
-17.68%
QTD
-0.19%
Financial performance
How have Apogee Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$216.87M
Net income
-$182.15M
Gross margin
N/A
Net margin
N/A
Apogee Therapeutics's operating income has shrunk by 133% YoY and by 22% QoQ
APGE's net income has dropped by 117% year-on-year and by 24% since the previous quarter
Price vs fundamentals
How does APGE's price correlate with its fundamentals
Growth
What is Apogee Therapeutics's growth rate over time
Valuation
What is Apogee Therapeutics stock price valuation
P/E
N/A
P/B
3.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 36% QoQ
APGE's equity has surged by 89% year-on-year but it is down by 2.4% since the previous quarter
APGE's P/B is 22% below its last 4 quarters average of 3.9
Efficiency
How efficient is Apogee Therapeutics business performance
APGE's return on equity has surged by 51% year-on-year but it is down by 11% since the previous quarter
The company's return on invested capital has surged by 50% YoY but it fell by 3.7% QoQ
Apogee Therapeutics's ROA has increased by 24% YoY but it has decreased by 11% from the previous quarter
Dividends
What is APGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APGE.
Financial health
How did Apogee Therapeutics financials performed over time
APGE's total assets has surged by 88% year-on-year but it is down by 2.9% since the previous quarter
Apogee Therapeutics's total liabilities has surged by 73% YoY but it has decreased by 11% QoQ
The debt is 98% less than the equity
APGE's debt to equity has soared by 100% YoY
APGE's equity has surged by 89% year-on-year but it is down by 2.4% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.